The latest announcement is out from 89bio (ETNB).
Charles McWherter, Ph.D., with a significant background in biopharmaceuticals, has been appointed as a Class I Director on the board of a company, where he will serve until the 2026 Annual Meeting of Stockholders. Renowned for his past roles, including President of R&D at CymaBay Therapeutics and executive positions at Pfizer and Sugen, Inc., Dr. McWherter brings a wealth of experience to his new role. His appointment has been publicly announced, and he will be compensated according to the company’s policies without any conflicts of interest or familial ties influencing his position.
Learn more about ETNB stock on TipRanks’ Stock Analysis page.
